A CRISPR-Cas Cure for HIV/AIDS.

Area of Science:

• Molecular Biology
• Virology
• Immunology

Background:

• Human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) remain a significant global health challenge.
• Current antiretroviral therapies manage viral replication but do not eliminate the virus or its latent reservoir.
• Gene therapy presents a novel approach to target and potentially eradicate HIV.

Purpose of the Study:

• To review the current state of CRISPR-Cas gene editing as a therapeutic strategy against HIV.
• To explore the interplay between HIV infection biology, host restriction factors, and gene editing.
• To discuss the potential of combined CRISPR-Cas approaches for HIV cure.

Main Methods:

• Review of existing literature on CRISPR-Cas systems and HIV gene therapy.
• Analysis of HIV infection mechanisms and host immune responses.
• Evaluation of strategies for targeting both viral and host genes.

Main Results:

• CRISPR-Cas gene editing platforms show significant promise for targeting the latent HIV reservoir.
• Combined approaches targeting host and viral genes can simultaneously activate antiviral factors and inhibit replication.
• Understanding HIV infection biology and host restriction factors is crucial for effective gene editing.

Conclusions:

• CRISPR-Cas gene editing is a leading candidate for developing a functional HIV cure.
• Overcoming challenges in delivery and specificity is key to clinical translation.
• Future research should focus on optimizing combined gene editing strategies for complete viral eradication.